Journal Home > Volume 11 , Issue 5
Food Science and Human Wellness 2022, 11(5): 1087-1100 https://doi.org/10.1016/j.fshw.2022.04.001
Review Article | Open Access | Issue | Published: 02 June 2022

Hypoglycemic natural products with in vivo activities and their mechanisms: a review

Show Author's Information Wenyi Maa,b,  Longgao Xiaoa,b,  Haiyang Liua( ),  Xiaojiang Haoa( )
State Key Laboratory of Phytochemistry and Plant Resources in West China, Yunnan Key Laboratory of Natural Medicinal Chemistry, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, China
University of Chinese Academy of Sciences, Beijing 100049, China

Peer review under responsibility of KeAi Communications Co., Ltd.

Keywords:
Mechanism, Diabetes, Natural products, Hypoglycemic effects
Cite this article:
Ma W, Xiao L, Liu H, et al. Hypoglycemic natural products with in vivo activities and their mechanisms: a review. Food Science and Human Wellness, 2022, 11(5): 1087-1100. https://doi.org/10.1016/j.fshw.2022.04.001
Download citation
EndNote(RIS)
BibTeX

603

Views

45

Downloads

Citations

15

Crossref

15

WoS

16

Scopus

0

CSCD

Abstract Full text About this article

Diabetes mellitus (DM) is a metabolic disorder disease, and the number of diabetic patients will reach 578 million by 2030 predictably. Currently, 8 classes of small molecular drugs are used for treating diabetes. However, these drugs cannot completely meet patients' needs, due to diabetic complications need to be addressed along with diabetes, such as nephropathy, and cardiovascular diseases. Besides, more types of drugs need to be provided for more choices. Hence, scientists still seek lead compounds with hypoglycemic effects. Natural products (NPs) are a reservoir of diverse structures and bioactivities with low toxicity and less side effects. And some of them show effects on diabetic complications, which is a significant idea for drug development. This review aims to summarize natural products with hypoglycemic effects and their details, such as potential mechanisms, biological data, and particularly their advantages in treating diabetes. Considering the huge number of NPs was reported with anti-diabetic activity, and some of them need to be re-validated, this review focuses on the bioactive compounds with in vivo activities. In the end, the trend of natural products treating diabetes was discussed. We hope this review provide a comprehensive and convincing summary, thus lending support to anti-diabetic natural products research.


menu
Abstract
Full text
Outline
About this article

Hypoglycemic natural products with in vivo activities and their mechanisms: a review

Show Author's information Wenyi Maa,b, Longgao Xiaoa,b, Haiyang Liua( ), Xiaojiang Haoa( )
State Key Laboratory of Phytochemistry and Plant Resources in West China, Yunnan Key Laboratory of Natural Medicinal Chemistry, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, China
University of Chinese Academy of Sciences, Beijing 100049, China

Peer review under responsibility of KeAi Communications Co., Ltd.

Abstract

Diabetes mellitus (DM) is a metabolic disorder disease, and the number of diabetic patients will reach 578 million by 2030 predictably. Currently, 8 classes of small molecular drugs are used for treating diabetes. However, these drugs cannot completely meet patients' needs, due to diabetic complications need to be addressed along with diabetes, such as nephropathy, and cardiovascular diseases. Besides, more types of drugs need to be provided for more choices. Hence, scientists still seek lead compounds with hypoglycemic effects. Natural products (NPs) are a reservoir of diverse structures and bioactivities with low toxicity and less side effects. And some of them show effects on diabetic complications, which is a significant idea for drug development. This review aims to summarize natural products with hypoglycemic effects and their details, such as potential mechanisms, biological data, and particularly their advantages in treating diabetes. Considering the huge number of NPs was reported with anti-diabetic activity, and some of them need to be re-validated, this review focuses on the bioactive compounds with in vivo activities. In the end, the trend of natural products treating diabetes was discussed. We hope this review provide a comprehensive and convincing summary, thus lending support to anti-diabetic natural products research.

Keywords: Mechanism, Diabetes, Natural products, Hypoglycemic effects

References(126)

[1]

N.G. Clark, K.M. Fox, S. Grandy, et al., Symptoms of diabetes and their association with the risk and presence of diabetes: findings from the study to help improve early evaluation and management of risk factors leading to diabetes (shield), Diabetes Care 30 (2007) 2868-2873. https://doi.org/10.2337/dc07-0816
DOI Google Scholar
[2]

J.L. Harding, M.E. Pavkov, D.J. Magliano, et al., Global trends in diabetes complications: a review of current evidence, Diabetologia 62 (2019) 3-16. https://doi.org/10.1007/s00125-018-4711-2
DOI Google Scholar
[3]

P. Saeedi, I. Petersohn, P. Salpea, et al., Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9(th) edition, Diabetes Res. Clin. Pract. 157 (2019) 107843. https://doi.org/10.1016/j.diabres.2019.107843
DOI Google Scholar
[4]

A. American Diabetes, 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021, Diabetes Care 44 (2021) S15-S33. https://doi.org/10.2337/dc21-S002
DOI Google Scholar
[5]

L.L. Wu, A.L. Wu, W.F. Peng, Research progress of Chinese herbal medicine treating diabetes mellitus, J. Pra. Trad. Chin. Int. Med. 33 (2019) 99-103
DOI Google Scholar
[6]

L.X. Liu, W. Wu, L.L. Pang, et al., Research progress on chemical composition, pharmacological action and clinical application of Gegen QInlian decoction, Chin. Arch. Trad. Chin. Med. 9 (2021) 1-15
Google Scholar
[7]

D.J. Newman, G.M. Cragg, Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019, J. Nat. Prod. 83 (2020) 770-803. https://doi.org/10.1021/acs.jnatprod.9b01285
DOI Google Scholar
[8]

C.J. Bailey, Metformin: historical overview, Diabetologia 60 (2017) 1566-1576. https://doi.org/10.1007/s00125-017-4318-z
DOI Google Scholar
[9]

B. Viollet, B. Guigas, N. Sanz Garcia, et al., Cellular and molecular mechanisms of metformin: an overview, Clin Sci (Lond). 122 (2012) 253-270. https://doi.org/10.1042/CS20110386
DOI Google Scholar
[10]

G. Rena, D.G. Hardie, E.R. Pearson, The mechanisms of action of metformin, Diabetologia 60 (2017) 1577-1585. https://doi.org/10.1007/s00125-017-4342-z
DOI Google Scholar
[11]

E.C. Chao, R.R. Henry, Sglt2 inhibition--a novel strategy for diabetes treatment, Nat. Rev. Drug Discov. 9 (2010) 551-559. https://doi.org/10.1038/nrd3180
DOI Google Scholar
[12]

J.R. Ehrenkranz, N.G. Lewis, C.R. Kahn, et al., Phlorizin: a review, Diabetes Metab. Res. Rev. 21 (2005) 31-38. https://doi.org/10.1002/dmrr.532
DOI Google Scholar
[13]

W. Blaschek, Natural products as lead compounds for sodium glucose cotransporter (sglt) inhibitors, Planta Med. 83 (2017) 985-993. https://doi.org/10.1055/s-0043-106050
DOI Google Scholar
[14]

D. Sola, L. Rossi, G.P. Schianca, et al., Sulfonylureas and their use in clinical practice, Arch. Med. Sci. 11 (2015) 840-848. https://doi.org/10.5114/aoms.2015.53304
DOI Google Scholar
[15]

A. Douros, S. Dell'Aniello, O.H.Y. Yu, et al., Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study, BMJ 362 (2018) k2693. https://doi.org/10.1136/bmj.k2693
DOI Google Scholar
[16]

A.M.K. Hansen, I.T. Christensen, J.B. Hansen, et al., Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1, Diabetes 51 (2002) 2789-2795. https://doi.org/10.2337/diabetes.51.9.2789
DOI Google Scholar
[17]

W. Lv, X. Wang, Q. Xu, et al., Mechanisms and characteristics of sulfonylureas and glinides, Curr. Top Med. Chem. 20 (2020) 37-56. https://doi.org/10.2174/1568026620666191224141617
DOI Google Scholar
[18]

J.J. DiNicolantonio, J. Bhutani, J.H. O'Keefe, Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes, Open Heart 2 (2015) e000327. https://doi.org/10.1136/openhrt-2015-000327
DOI Google Scholar
[19]

R.H. Unger, Lipotoxicity in the pathogenesis of obesity-dependent niddm - genetic and clinical implications, Diabetes 44 (1995) 863-870. https://doi.org/10.2337/diabetes.44.8.863
DOI Google Scholar
[20]

M. Stumvoll, H.U. Häring, Glitazones: clinical effects and molecular mechanisms, Ann. Med. 34 (2009) 217-224. https://doi.org/10.1080/ann.34.3.217.224
DOI Google Scholar
[21]

C.E. Quinn, P.K. Hamilton, C.J. Lockhart, et al., Thiazolidinediones: effects on insulin resistance and the cardiovascular system, Br. J. Pharmacol. 153 (2008) 636-645. https://doi.org/10.1038/sj.bjp.0707452
DOI Google Scholar
[22]

D. Hinnen, Glucagon-like peptide 1 receptor agonists for type 2 diabetes, Diabetes Spectr. 30 (2017) 202-210. https://doi.org/10.2337/ds16-0026
DOI Google Scholar
[23]

T.D. Filippatos, T.V. Panagiotopoulou, M.S. Elisaf, Adverse effects of Glp-1 receptor agonists, Rev. Diabet. Stud. 11 (2014) 202-230. https://doi.org/10.1900/RDS.2014.11.202
DOI Google Scholar
[24]

D. Dicker, Dpp-4 inhibitors: impact on glycemic control and cardiovascular risk factors, Diabetes Care 34(Suppl 2) (2011) S276-S278. https://doi.org/10.2337/dc11-s229
DOI Google Scholar
[25]

B. Gallwitz, Clinical use of DPP-4 inhibitors, Front. Endocrinol (Lausanne) 10 (2019) 389. https://doi.org/10.3389/fendo.2019.00389
DOI Google Scholar
[26]

M.A. Nauck, Update on developments with sglt2 inhibitors in the management of type 2 diabetes, Drug Des. Devel. Ther. 8 (2014) 1335-1380. https://doi.org/10.2147/DDDT.S50773
DOI Google Scholar
[27]

M.A. Abdul-Ghani, L. Norton, R.A. Defronzo, Role of sodium-glucose cotransporter 2 (sglt 2) inhibitors in the treatment of type 2 diabetes, Endocr. Rev. 32 (2011) 515-531. https://doi.org/10.1210/er.2010-0029
DOI Google Scholar
[28]

D.M. Martin, J. Gershenzon, J. Bohlmann, Induction of volatile terpene biosynthesis and diurnal emission by methyl jasmonate in foliage of norway spruce, Plant Physiol. 132 (2003) 1586-1599. https://doi.org/10.1104/pp.103.021196
DOI Google Scholar
[29]
L.P. Christensen, Ginsenosides Chemistry, Biosynthesis, Analysis, and Potential Health Effects. Chapter 1 Ginsenosides, Elsevier. 2008, pp. 1-99. https://doi.org/10.1016/S1043-4526(08)00401-4
DOI
[30]

X.D. Yang, Y.Y. Yang, D.S. Ouyang, et al., A review of biotransformation and pharmacology of ginsenoside compound K, Fitoterapia 100 (2015) 208-220. https://doi.org/10.1016/j.fitote.2014.11.019
DOI Google Scholar
[31]

G.C. Han, S.K. Ko, J.H. Sung, et al., Compound K enhances insulin secretion with beneficial metabolic effects in db/db mice, J. Arg. Food Chem. 55 (2007) 10641-10648. https://doi.org/10.1021/jf0722598
DOI Google Scholar
[32]

F.Y. Guan, J. Gu, W. Li, et al., Compound K protects pancreatic islet cells against apoptosis through inhibition of the AMPK/JNK pathway in type 2 diabetic mice and in min6 beta-cells, Life Sci. 107 (2014) 42-49. https://doi.org/10.1016/j.lfs.2014.04.034
DOI Google Scholar
[33]

S. Wei, W. Li, Y. Yu, et al., Ginsenoside compound k suppresses the hepatic gluconeogenesis via activating adenosine-5'monophosphate kinase: a study in vitro and in vivo, Life Sci. 139 (2015) 8-15. https://doi.org/10.1016/j.lfs.2015.07.032
DOI Google Scholar
[34]

S. Jiang, D. Ren, J. Li, et al., Effects of compound K on hyperglycemia and insulin resistance in rats with type 2 diabetes mellitus, Fitoterapia 95 (2014) 58-64. https://doi.org/10.1016/j.fitote.2014.02.017
DOI Google Scholar
[35]

A. Lim, Diabetic nephropathy - complications and treatment, Int. J. Nephrol. Renovasc. Dis. 7 (2014) 361-381. https://doi.org/10.2147/IJNRD.S40172
DOI Google Scholar
[36]

C. Mora-Fernandez, V. Dominguez-Pimentel, M.M. de Fuentes, et al., Diabetic kidney disease: from physiology to therapeutics, J. Physiol. 592 (2014) 3997-4012. https://doi.org/10.1113/jphysiol.2014.272328
DOI Google Scholar
[37]

W. Song, L. Wei, Y. Du, et al., Protective effect of ginsenoside metabolite compound K against diabetic nephropathy by inhibiting NLRP3 inflammasome activation and NF-kappaB/p38 signaling pathway in high-fat diet/streptozotocin-induced diabetic mice, Int. Immunopharmacol. 63 (2018) 227-238. https://doi.org/10.1016/j.intimp.2018.07.027
DOI Google Scholar
[38]

W. Li, M. Zhang, J. Gu, et al., Hypoglycemic effect of protopanaxadiol-type ginsenosides and compound k on type 2 diabetes mice induced by high-fat diet combining with streptozotocin via suppression of hepatic gluconeogenesis, Fitoterapia. 83 (2012) 192-198. https://doi.org/10.1016/j.fitote.2011.10.011
DOI Google Scholar
[39]

Y. Wang, H. Wang, Y. Liu, et al., Antihyperglycemic effect of ginsenoside Rh2 by inducing islet beta-cell regeneration in mice, Horm. Metab. Res. 44 (2012) 33-40. https://doi.org/10.1055/s-0031-1295416
DOI Google Scholar
[40]

W.K. Lee, S.T. Kao, I.M. Liu, et al., Ginsenoside Rh2 is one of the active principles of panax ginseng root to improve insulin sensitivity in fructose-rich chow-fed rats, Horm. Metab. Res. 39 (2007) 347-354. https://doi.org/10.1055/s-2007-976537
DOI Google Scholar
[41]

D.M. Lai, Y.K. Tu, I.M. Liu, et al., Mediation of beta-endorphin by ginsenoside Rh2 to lower plasma glucose in streptozotocin-induced diabetic rats, Planta Med. 72 (2006) 9-13. https://doi.org/10.1055/s-2005-916177
DOI Google Scholar
[42]

N. Xiao, M.D. Lou, Y.T. Lu, et al., Ginsenoside Rg5 attenuates hepatic glucagon response via suppression of succinate-associated HIF-1alpha induction in HFD-fed mice, Diabetologia 60 (2017) 1084-1093. https://doi.org/10.1007/s00125-017-4238-y
DOI Google Scholar
[43]

Y. Wei, H. Yang, C. Zhu, et al., Hypoglycemic effect of ginsenoside Rg5 mediated partly by modulating gut microbiota dysbiosis in diabetic db/db mice, J. Agr. Food Chem. 68 (2020) 5107-5117. https://doi.org/10.1021/acs.jafc.0c00605
DOI Google Scholar
[44]

Y. Wei, H. Yang, C. Zhu, et al., Ginsenoside Rg5 relieves type 2 diabetes by improving hepatic insulin resistance in db/db mice, J. Funct. Foods 71 (2020) https://doi.org/10.1016/j.jff.2020.104014
DOI Google Scholar
[45]

Y. Xiong, L. Shen, K.J. Liu, et al., Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats, Diabetes 59 (2010) 2505-2512. https://doi.org/10.2337/db10-0315
DOI Google Scholar
[46]

B. Song, L. Ding, H. Zhang, et al., Ginsenoside Rb1 increases insulin sensitivity through suppressing 11 beta-hydroxysteroid dehydrogenase type I, Am. J. Transl. Res. 9 (2017) 1049-1057
Google Scholar
[47]

M.D. Lou, J. Li, Y. Cheng, et al., Glucagon up-regulates hepatic mitochondrial pyruvate carrier 1 through camp-responsive element-binding protein; inhibition of hepatic gluconeogenesis by ginsenoside Rb1, Br. J. Pharmacol. 176 (2019) 2962-2976. https://doi.org/10.1111/bph.14758
DOI Google Scholar
[48]

S. Dai, Y. Hong, J. Xu, et al., Ginsenoside Rb2 promotes glucose metabolism and attenuates fat accumulation via Akt-dependent mechanisms, Biomed. Pharmacother. 100 (2018) 93-100. https://doi.org/10.1016/j.biopha.2018.01.111
DOI Google Scholar
[49]

Q. Huang, T. Wang, L. Yang, et al., Ginsenoside Rb2 alleviates hepatic lipid accumulation by restoring autophagy via induction of Sirt1 and activation of AMPK, Int. J. Mol. Sci. 18 (2017) 1063. https://doi.org/10.3390/ijms18051063
DOI Google Scholar
[50]

T. Yokozawa, T. Kobayashi, H. Oura, et al., Studies on the mechanism of the hypoglycemic activity of ginsenoside-Rb2 in streptozotocin-diabetic rats, Chem. Pharm. Bull. 33 (1985) 869-872
DOI Google Scholar
[51]

Q.T. Bu, W.Y. Zhang, Q.C. Chen, et al., Anti-diabetic effect of ginsenoside Rb-3 in alloxan-induced diabetic mice, Med. Chem. 8 (2012) 934-941
DOI Google Scholar
[52]

H. Liu, J. Wang, M. Liu, et al., Antiobesity effects of ginsenoside Rg1 on 3t3-l1 preadipocytes and high fat diet-induced obese mice mediated by AMPK, Nutrients 10 (2018) 830. https://doi.org/10.3390/nu10070830
DOI Google Scholar
[53]

Q. Liu, F.G. Zhang, W.S. Zhang, et al., Ginsenoside Rg1 inhibits glucagon-induced hepatic gluconeogenesis through Akt-FoxO1 interaction, Theranostics 7 (2017) 4001-4012. https://doi.org/10.7150/thno.18788
DOI Google Scholar
[54]

Y. Liu, J. Deng, D. Fan, Ginsenoside Rk3 ameliorates high-fat-diet/streptozocin induced type 2 diabetes mellitus in mice via the AMPK/Akt signaling pathway, Food Funct. 10 (2019) 2538-2551. https://doi.org/10.1039/c9fo00095j
DOI Google Scholar
[55]

J.M. Kim, C.H. Park, S.K. Park, et al., Ginsenoside re ameliorates brain insulin resistance and cognitive dysfunction in high fat diet-induced C57BL/6 mice, J. Agr. Food Chem. 65 (2017) 2719-2729. https://doi.org/10.1021/acs.jafc.7b00297
DOI Google Scholar
[56]

Z. Zhang, X. Li, W. Lv, et al., Ginsenoside Re reduces insulin resistance through inhibition of c-Jun NH2-terminal kinase and nuclear factor-kappaB, Mol. Endocrinol. 22 (2008) 186-195. https://doi.org/10.1210/me.2007-0119
DOI Google Scholar
[57]

D. Gao, Q. Li, Y. Li, et al., Antidiabetic and antioxidant effects of oleanolic acid from ligustrum lucidum ait in alloxan-induced diabetic rats, Phytother. Res. 23 (2009) 1257-1262. https://doi.org/10.1002/ptr.2603
DOI Google Scholar
[58]

D. Gao, Q. Li, Y. Li, et al., Antidiabetic potential of oleanolic acid from Ligustrum lucidum Ait, Can. J. Physiol. Pharmacol. 85 (2007) 1076-1083. https://doi.org/10.1139/Y07-098
DOI Google Scholar
[59]

S. van Dieren, J.W. Beulens, Y.T. van der Schouw, et al., The global burden of diabetes and its complications: an emerging pandemic, Eur. J. Cardiovasc. Prev. Rehabil. 17(Suppl 1) (2010) 3-8. https://doi.org/10.1097/01.hjr.0000368191.86614.5a
DOI Google Scholar
[60]

M. Gamede, L. Mabuza, P. Ngubane, et al., Plant-derived Oleanolic acid (OA) ameliorates risk factors of cardiovascular diseases in a diet-induced pre-diabetic rat model: effects on selected cardiovascular risk factors, Molecules 24 (2019) https://doi.org/10.3390/molecules24020340
DOI Google Scholar
[61]

E.S. Lee, H.M. Kim, J.S. Kang, et al., Oleanolic acid and n-acetylcysteine ameliorate diabetic nephropathy through reduction of oxidative stress and endoplasmic reticulum stress in a type 2 diabetic rat model, Nephrol. Dial. Transplant 31 (2016) 391-400. https://doi.org/10.1093/ndt/gfv377
DOI Google Scholar
[62]

S.R. Naik, J.M. Barbosa-Filho, J.N. Dhuley, et al., Probable mechanism of hypoglycemic activity of bassic acid, a natural product isolated from bumelia-sartorum, J. Ethnopharmacol. 33 (1991) 37-44. https://doi.org/10.1016/0378-8741(91)90158-a
DOI Google Scholar
[63]

K.N. Zhu, C.H. Jiang, Y.S. Tian, et al., Two triterpeniods from Cyclocarya paliurus (Batal) Iljinsk (Juglandaceae) promote glucose uptake in 3T3-L1 adipocytes: the relationship to AMPK activation, Phytomedicine 22 (2015) 837-846. https://doi.org/10.1016/j.phymed.2015.05.058
DOI Google Scholar
[64]

H. Xiong, S. Zhang, Z. Zhao, et al., Antidiabetic activities of entagenic acid in type 2 diabetic db/db mice and l6 myotubes via AMPK/GLUT4 pathway, J. Ethnopharmacol. 211 (2018) 366-374. https://doi.org/10.1016/j.jep.2017.10.004
DOI Google Scholar
[65]

J. Chen, W.L. Li, J.L. Wu, et al., Euscaphic acid, a new hypoglycemic natural product from folium eriobotryae, Pharmazie 63 (2008) 765-767. https://doi.org/10.1691/ph.2008.8583
DOI Google Scholar
[66]

B. Jayaprakasam, L.K. Olson, R.E. Schutzki, et al., Amelioration of obesity and glucose intolerance in high-fat-fed c57bl/6 mice by anthocyanins and ursolic acid in cornelian cherry (Cornus mas), J. Arg. Food Chem. 54 (2006) 243-248. https://doi.org/10.1021/jf0520342
DOI Google Scholar
[67]

C.L. de Melo, M.G. Queiroz, A.C.Arruda Filho, et al., Betulinic acid, a natural pentacyclic triterpenoid, prevents abdominal fat accumulation in mice fed a high-fat diet, J. Agr. Food Chem. 57 (2009) 8776-8781. https://doi.org/10.1021/jf900768w
DOI Google Scholar
[68]

C.H. Lin, L.W. Hsiao, Y.H. Kuo, et al., Antidiabetic and antihyperlipidemic effects of sulphurenic acid, a triterpenoid compound from Antrodia camphorata, in streptozotocin-induced diabetic mice, Int. J. Mol. Sci. 20 (2019) 4897. https://doi.org/10.3390/ijms20194897
DOI Google Scholar
[69]

S.E. Mabhida, R.A. Mosa, D. Penduka, et al., A lanosteryl triterpene from protorhus longifolia improves glucose tolerance and pancreatic beta cell Ultrastructure in type 2 diabetic rats, Molecules 22 (2017) 1252. https://doi.org/10.3390/molecules22081252
DOI Google Scholar
[70]

N.K. Hoa, A. Norberg, R. Sillard, et al., The possible mechanisms by which phanoside stimulates insulin secretion from rat islets, J. Endocrinol. 192 (2007) 389-394. https://doi.org/10.1677/joe.1.06948
DOI Google Scholar
[71]

C. Zhang, L. Gui, Y. Xu, et al., Preventive effects of andrographolide on the development of diabetes in autoimmune diabetic nod mice by inducing immune tolerance, Int. Immunopharmacol 16 (2013) 451-456. https://doi.org/10.1016/j.intimp.2013.05.002
DOI Google Scholar
[72]

M.G. Campos, M. Oropeza, C. Torres-Sosa, et al., Sesquiterpenoids from antidiabetic Psacalium decompositum block ATP sensitive potassium channels, J. Ethnopharmacol. 123 (2009) 489-493. https://doi.org/10.1016/j.jep.2009.03.003
DOI Google Scholar
[73]

C. Serra-Barcellona, N.C. Habib, S.M. Honore, et al., Enhydrin regulates postprandial hyperglycemia in diabetic rats by inhibition of α-glucosidase activity, Plant Foods Hum. Nutr. 72 (2017) 156-160. https://doi.org/10.1007/s11130-017-0600-y
DOI Google Scholar
[74]

L. Guan, H. Feng, D. Gong, et al., Genipin ameliorates age-related insulin resistance through inhibiting hepatic oxidative stress and mitochondrial dysfunction, Exp. Gerontol. 48 (2013) 1387-1394. https://doi.org/10.1016/j.exger.2013.09.001
DOI Google Scholar
[75]

K. Kojima, T. Shimada, Y. Nagareda, et al., Preventive effect of geniposide on metabolic disease status in spontaneously obese type 2 diabetic mice and free fatty acid-treated HEPG2 cells, Biol. Pharm. Bull. 34 (2011) 1613-1618. https://doi.org/10.1248/bpb.34.1613
DOI Google Scholar
[76]

R. Manikandan, R. Thiagarajan, S. Beulaja, et al., 1, 2-Di-substituted idopyranose from Vitex negundo L. Protects against streptozotocin-induced diabetes by inhibiting nuclear factor-kappa B and inducible nitric oxide synthase expression, Microsc. Res. Tech. 74 (2011) 301-307. https://doi.org/10.1002/jemt.20904
DOI Google Scholar
[77]

L.C. Lin, L.C. Lee, C. Huang, et al., Effects of boschnaloside from boschniakia rossica on dysglycemia and islet dysfunction in severely diabetic mice through modulating the action of glucagon-like peptide-1, Phytomedicine 62 (2019) 152946. https://doi.org/10.1016/j.phymed.2019.152946
DOI Google Scholar
[78]

J.P. Shieh, K.C. Cheng, H.H. Chung, et al., Plasma glucose lowering mechanisms of catalpol, an active principle from roots of Rehmannia glutinosa, in streptozotocin-induced diabetic rats, J. Agr. Food Chem. 59 (2011) 3747-3753. https://doi.org/10.1021/jf200069t
DOI Google Scholar
[79]

J. Yan, C. Wang, Y. Jin, et al., Catalpol ameliorates hepatic insulin resistance in type 2 diabetes through acting on AMPK/NOX4/PI3K/Akt pathway, Pharmacol. Res. 130 (2018) 466-480. https://doi.org/10.1016/j.phrs.2017.12.026
DOI Google Scholar
[80]

J. Peng, T.T. Zheng, X. Li, et al., Plant-derived alkaloids: The promising disease-modifying agents for inflammatory bowel disease, Front. Pharmacol. 10 (2019) 351. https://doi.org/10.3389/fphar.2019.00351
DOI Google Scholar
[81]

J. Yin, J. Ye, W. Jia, Effects and mechanisms of berberine in diabetes treatment, Acta. Pharm. Sin. B 2 (2012) 327-334. https://doi.org/10.1016/j.apsb.2012.06.003
DOI Google Scholar
[82]

W.J. Kong, H. Zhang, D.Q. Song, et al., Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin, Receptor Expression Metabolism 58 (2009) 109-119. https://doi.org/10.1016/j.metabol.2008.08.013
DOI Google Scholar
[83]

W.S. Kim, Y.S. Lee, S.H. Cha, et al., Berberine improves lipid dysregulation in obesity by controlling central and peripheral ampk activity, Am. J. Physiol. Endocrinol. Metab. 296 (2009) E812-E819. https://doi.org/10.1152/ajpendo.90710.2008
DOI Google Scholar
[84]

H. Xie, Q. Wang, X. Zhang, et al., Possible therapeutic potential of berberine in the treatment of STZ plus HFD-induced diabetic osteoporosis, Biomed. Pharmacother. 108 (2018) 280-287. https://doi.org/10.1016/j.biopha.2018.08.131
DOI Google Scholar
[85]

W. Chang, L. Chen, G.M. Hatch, Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies, Biochem. Cell Biol. 93 (2015) 479-486. https://doi.org/10.1139/bcb-2014-0107
DOI Google Scholar
[86]

W. Zheng, L. Qiu, R. Wang, et al., Selective targeting of ppar gamma by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency, Sci. Rep. UK. 5 (2015). https://doi.org/10.1038/srep12222
DOI Google Scholar
[87]

G. Selvaraj, S. Kaliamurthi, R. Thirugnasambandan, Effect of glycosin alkaloid from rhizophora apiculata in non-insulin dependent diabetic rats and its mechanism of action: in vivo and in silico studies, Phytomedicine 23 (2016) 632-640. https://doi.org/10.1016/j.phymed.2016.03.004
DOI Google Scholar
[88]

T. Wang, T. Kusudo, T. Takeuchi, et al., Evodiamine inhibits insulin-stimulated mTOR-S6K activation and IRS1 serine phosphorylation in adipocytes and improves glucose tolerance in obese/diabetic mice, PLoS One 8 (2013) e83264. https://doi.org/10.1371/journal.pone.0083264
DOI Google Scholar
[89]

O. Yoshinari, K. Igarashi, Anti-diabetic effect of trigonelline and nicotinic acid, on KK-A(y) mice, Curr. Med. Chem. 17 (2010) 2196-2202. https://doi.org/10.2174/092986710791299902
DOI Google Scholar
[90]

Z.Q. Liu, T. Liu, C. Chen, et al., Fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in insulin-resistance HEPG2 cells and shows anti-diabetic effect in diabetic KKAy mice, Toxicol. Aool. Pharm. 285 (2015) 61-70. https://doi.org/10.1016/j.taap.2015.03.011
DOI Google Scholar
[91]

A. Maeda, T. Shirao, D. Shirasaya, et al., Piperine promotes glucose uptake through ros-dependent activation of the CaMKK/AMPK signaling pathway in skeletal muscle, Mol. Nutr. Food Res. 62 (2018) e1800086. https://doi.org/10.1002/mnfr.201800086
DOI Google Scholar
[92]

A.N. Panche, A.D. Diwan, S.R. Chandra, Flavonoids: an overview, J. Nutr. Sci. 5 (2016) e47. https://doi.org/10.1017/jns.2016.41
DOI Google Scholar
[93]

B. Singh, P. Kaur, Gopichand, et al., Biology and chemistry of Ginkgo biloba, Fitoterapia 79 (2008) 401-418. https://doi.org/10.1016/j.fitote.2008.05.007
DOI Google Scholar
[94]

H. Alkhalidy, W. Moore, A. Wang, et al., Kaempferol ameliorates hyperglycemia through suppressing hepatic gluconeogenesis and enhancing hepatic insulin sensitivity in diet-induced obese mice, J. Nutr. Biochem. 58 (2018) 90-101. https://doi.org/10.1016/j.jnutbio.2018.04.014
DOI Google Scholar
[95]

A.K. Keshari, G. Kumar, P.S. Kushwaha, et al., Isolated flavonoids from ficus racemosa stem bark possess antidiabetic, hypolipidemic and protective effects in albino wistar rats, J. Ethnopharmacol. 181 (2016) 252-262. https://doi.org/10.1016/j.jep.2016.02.004
DOI Google Scholar
[96]

M.M. Alam, D. Meerza, I. Naseem, Protective effect of quercetin on hyperglycemia, oxidative stress and DNA damage in alloxan induced type 2 diabetic mice, Life Sci. 109 (2014) 8-14. https://doi.org/10.1016/j.lfs.2014.06.005
DOI Google Scholar
[97]

D.K. Yang, H.S. Kang, Anti-diabetic effect of cotreatment with quercetin and resveratrol in streptozotocin-induced diabetic rats, Biomol. Ther. (Seoul). 26 (2018) 130-138. https://doi.org/10.4062/biomolther.2017.254
DOI Google Scholar
[98]

A.K. Shetty, R. Rashmi, M.G.R. Rajan, et al., Antidiabetic influence of quercetin in streptozotocin-induced diabetic rats, Nrtr. Res. 24 (2004) 373-381. https://doi.org/10.1016/j.nutres.2003.11.010
DOI Google Scholar
[99]

I.M. Liu, T.F. Tzeng, S.S. Liou, et al., Improvement of insulin sensitivity in obese zucker rats by myricetin extracted from Abelmoschus moschatus, Planta Med. 73 (2007) 1054-1060. https://doi.org/10.1055/s-2007-981577
DOI Google Scholar
[100]

S. George, S.A. Nair, A.J. Johnson, et al., O-prenylated flavonoid, an antidiabetes constituent in melicope lunu-ankenda, J. Ethnopharmacol. 168 (2015) 158-163. https://doi.org/10.1016/j.jep.2015.03.060
DOI Google Scholar
[101]

Z. Fu, W. Zhang, W. Zhen, et al., Genistein induces pancreatic β-cell proliferation through activation of multiple signaling pathways and prevents insulin-deficient diabetes in mice, Endocrinology 151 (2010) 3026-3037. https://doi.org/10.1210/en.2009-1294
DOI Google Scholar
[102]

L.H. Cazarolli, P. Folador, H.H. Moresco, et al., Mechanism of action of the stimulatory effect of apigenin-6-c-(2"-O-α-L-rhamnopyranosyl)-β-L-fucopyranoside on C-14-glucose uptake, Chem. Bio. Interact. 179 (2009) 407-412. https://doi.org/10.1016/j.cbi.2008.11.012
DOI Google Scholar
[103]

L. Rossetti, D. Smith, G.I. Shulman, et al., Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats, J. Chin. Invest. 79 (1987) 1510-1515. https://doi.org/10.1172/jci112981
DOI Google Scholar
[104]

M.J. Son, M. Minakawa, Y. Miura, et al., Aspalathin improves hyperglycemia and glucose intolerance in obese diabetic ob/ob mice, Eur. J. Nutr. 52 (2013) 1607-1619. https://doi.org/10.1007/s00394-012-0466-6
DOI Google Scholar
[105]

C.P. Colturato, R.P. Constantin, A.S. Maeda et al., Metabolic effects of silibinin in the rat liver, Chem. Biol. Interact. 195 (2012) 119-132. https://doi.org/10.1016/j.cbi.2011.11.006
DOI Google Scholar
[106]

Y. Liu, Y.Q. Du, J.H. Wang, et al., Structural analysis and antioxidant activities of polysaccharide isolated from Jinqian mushroom, Int. J. Biol. Macromol. 64 (2014) 63-68. https://doi.org/10.1016/j.ijbiomac.2013.11.029
DOI Google Scholar
[107]

X.F. Bao, Z. Wang, J.N. Fang, et al., Structural features of an immunostimulating and antioxidant acidic polysaccharide from the seeds of cuscuta chinensis, Planta Medica. 68 (2002) 237-243. https://doi.org/10.1055/s-2002-23133
DOI Google Scholar
[108]

J. Lu, R. He, P. Sun, et al., Molecular mechanisms of bioactive polysaccharides from Ganoderma lucidum (lingzhi), a review, Int. J. Biol. Macromol. 150 (2020) 765-774. https://doi.org/10.1016/j.ijbiomac.2020.02.035
DOI Google Scholar
[109]

D. Cor, Z. Knez, M. Knez Hrncic, Antitumour, antimicrobial, antioxidant and antiacetylcholinesterase effect of Ganoderma lucidum terpenoids and polysaccharides: a review, Molecules 23 (2018). https://doi.org/10.3390/molecules23030649
DOI Google Scholar
[110]

Y. Liu, Y.Q. Du, J.H. Wang, et al., Structural analysis and antioxidant activities of polysaccharide isolated from jinqian mushroom, Int. J. Biol. Macromol. 64 (2014) 63-68. https://doi.org/10.1016/j.ijbiomac.2013.11.029
DOI Google Scholar
[111]

J. Zheng, B. Yang, Y. Yu, et al., Ganoderma lucidum polysaccharides exert anti-hyperglycemic effect on streptozotocin-induced diabetic rats through affecting beta-cells, Comb. Chem. High. T. Scr. 15 (2012) 542-550. https://doi.org/10.2174/138620712801619168
DOI Google Scholar
[112]

C. Xiao, Q.P. Wu, W. Cai, et al., Hypoglycemic effects of Ganoderma lucidum polysaccharides in type 2 diabetic mice, Arch. Pharm. Res. 35 (2012) 1793-1801. https://doi.org/10.1007/s12272-012-1012-z
DOI Google Scholar
[113]

C. Xiao, Q. Wu, J. Zhang, et al., Antidiabetic activity of Ganoderma lucidum polysaccharides F31 down-regulated hepatic glucose regulatory enzymes in diabetic mice, J. Ethnopharmacol. 196 (2017) 47-57. https://doi.org/10.1016/j.jep.2016.11.044
DOI Google Scholar
[114]

Y. Chen, Y. Liu, M.M.R. Sarker, et al., Structural characterization and antidiabetic potential of a novel heteropolysaccharide from Grifola frondosa via IRS1/PI3K-JNK signaling pathways, Carbohydr. Polym. 198 (2018) 452-461. https://doi.org/10.1016/j.carbpol.2018.06.077
DOI Google Scholar
[115]

N. Yang, M. Zhao, B. Zhu, et al., Anti-diabetic effects of polysaccharides from Opuntia monacantha cladode in normal and streptozotocin-induced diabetic rats, Innov. Food Sci. Emerg. 9 (2008) 570-574. https://doi.org/10.1016/j.ifset.2007.12.003
DOI Google Scholar
[116]

J. Zhu, W. Liu, J. Yu, et al., Characterization and hypoglycemic effect of a polysaccharide extracted from the fruit of Lycium barbarum L, Carbohydr. Polym. 98 (2013) 8-16. https://doi.org/10.1016/j.carbpol.2013.04.057
DOI Google Scholar
[117]

J. Wang, W. Jin, W. Zhang, et al., Hypoglycemic property of acidic polysaccharide extracted from Saccharina japonica and its potential mechanism, Carbohydr. Polym. 95 (2013) 143-147. https://doi.org/10.1016/j.carbpol.2013.02.076
DOI Google Scholar
[118]

S.F. Nabavi, R. Thiagarajan, L. Rastrelli, et al., Curcumin: a natural product for diabetes and its complications, Curr. Top. Med. Chem. 15 (2015) 2445-2455. https://doi.org/10.2174/1568026615666150619142519
DOI Google Scholar
[119]

J. Xue, W. Ding, Y. Liu, Anti-diabetic effects of emodin involved in the activation of ppargamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice, Fitoterapia 81 (2010) 173-177. https://doi.org/10.1016/j.fitote.2009.08.020
DOI Google Scholar
[120]
Y. Song, X. Fan, Z. Guo, et al., Therapeutic effects of emodin in type 2 diabetes mellitus in KKAy mouse model, Int. J. Clin. Exp. Med. https://doi.org/10 (2017) 14408-14413
[121]

S. Abu Eid, M. Adams, T. Scherer, et al., Emodin, a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents, Eur. J. Pharmacol. 798 (2017) 77-84. https://doi.org/10.1016/j.ejphar.2017.01.022
DOI Google Scholar
[122]

S. Zhang, Y. Ma, J. Li, et al., Molecular matchmaking between the popular weight-loss herb Hoodia gordonii and GPR119, a potential drug target for metabolic disorder, Proc. Natl. Acad. Sci. U.S.A. 111 (2014) 14571-14576. https://doi.org/10.1073/pnas.1324130111
DOI Google Scholar
[123]

H.S. Hansen, M.M. Rosenkilde, J.J. Holst, et al., GPR119 as a fat sensor, Trends Pharmacol. Sci. 33 (2012) 374-381. https://doi.org/10.1016/j.tips.2012.03.014
DOI Google Scholar
[124]

C.I. Chang, C.M. Hsu, T.S. Li, et al., Constituents of the stem of Cucurbita moschata exhibit antidiabetic activities through multiple mechanisms, J. Funct. Foods 10 (2014) 260-273. https://doi.org/10.1016/j.jff.2014.06.017
DOI Google Scholar
[125]

L. Chen, S. Zheng, M. Huang, et al., Β-ecdysterone from cyanotis arachnoidea exerts hypoglycemic effects through activating IRS-1/AKT/GLUT4 and IRS-1/AKT/GLUT2 signal pathways in KK-Ay mice, J. Funct. Foods 39 (2017) 123-132. https://doi.org/10.1016/j.jff.2017.09.061
DOI Google Scholar
[126]

M. Xiong, Y. Huang, Y. Liu, et al., Antidiabetic activity of ergosterol from Pleurotus ostreatus in KK-A(y) mice with spontaneous type 2 diabetes mellitus, Mol. Nutr. Food. Res. 62 (2018) https://doi.org/10.1002/mnfr.201700444
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 10 August 2021
Revised: 24 August 2021
Accepted: 10 November 2021
Published: 02 June 2022
Issue date: September 2022

Copyright

© 2022 Beijing Academy of Food Sciences.

Acknowledgements

Acknowledgements

This work was financially supported by the Natural Science Foundation of China (U1802287, 32000280, and 31770391) and Ten Thousand Talents Plan of Yunnan Province for Industrial Technology Leading Talents.

Rights and permissions

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Return